Chemotherapy drugs or toxic chemicals which are detoxified through hepatic glucuronidaiton can be reactivated by eβG back to toxic form and thus inducing intestine damage, diarrhea, carcinogenesis, and colon cancer. We developed eβG specific inhibitor as a novel chemotherapy adjuvant or chemoprevention drug for preventing chemical-induced damage and the development of colon cancer in FAP patients.

Bacterial βG-specific inhibitor as a novel drug for preventing CID and colon cancer, which has following characteristics: (1) specific inhibition of intestinal eβG, (2) highest inhibit effect and lowest toxicity, (3) does not affect the growth of probiotics, (4) specific act in the intestine, (5) widely used to prevent CID, (6) does not affect the drug efficacy, (7) can prevent colorectal cancer.

Chemotherapy adjuvant and chemoprevention drug to prevent chemotherapy-induced intestinal damage and diarrhea, thus improving patients＇ quality of life and increasing patient＇s drug tolerance to increase therapy efficacy.
Treatment for FAP to specific inhibit eβG to reduce polyp development, exacerbation and prevent the occurrence of colorectal cancer.